Centralization and cross-checking of product safety update reports and their publication by independent bodies would also be of significant interest. In the meantime, clinicians will need to rely on analyses such as those presented here for making informed choices on treatment options. TGF-beta/Smad inhibitor Acknowledgments Bayer Pharma AG provided all authors with free access to the moxifloxacin clinical database. Highfield Communication Consultancy Ltd (Oxford, UK) [funded by Bayer Pharma] provided editorial assistance in the preparation of this manuscript. The analysis was jointly designed and conducted and the results interpreted by all authors, who
also prepared and approved the manuscript. The clinical relevance of all results has also been assessed by Paul M. Tulkens and Pierre Arvis. Paul M. Tulkens has received research grants and honoraria (related to published
studies and presentations about moxifloxacin but not to this work) from Bayer Pharma, Sanofi-Aventis, Bristol-Myers/Squibb, KU-57788 molecular weight Pfizer, and GlaxoSmithKline. Pierre Arvis and Frank Kruesmann are employees of Bayer Santé SAS and Bayer Pharma AG, respectively. References 1. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections: full version. Clin Microbiol Infect 2011; 17 Suppl. 6: E1–59.PubMedCrossRef 2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management this website of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl. 2: S27–72.PubMedCrossRef 3. Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir
J 2003; 10 Suppl. B: 3B–32B.PubMed 4. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50 (2): 133–64.PubMedCrossRef 5. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130 (1 Suppl.): 1–45.PubMed 6. Sociedad Española de Quimioterapia, Sociedad Española de Otorrinolaringología y Patología Cérvico-Facial. Diagnosis and antimicrobial treatment of sinusitis. Rev Esp Quimioter 2003; 16 (2): 239–51. 7. Clinical Effectiveness Group, British Nepicastat cell line Association for Sexual Health and HIV. UK national guideline for the management of pelvic inflammatory disease 2011 (updated June 2011) [online]. Available from URL: http://www.bashh.org/documents/3572 [Accessed 2012 Jan 28]. 8. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41 (10): 1373–406.PubMedCrossRef 9.